Ossur hf ( (OSSFF) ) has released its Q2 earnings. Here is a breakdown of the information Ossur hf presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Embla Medical hf, a leader in the prosthetics and orthotics industry, has reported its Q2 2025 earnings, showcasing a steady growth trajectory despite certain market challenges. The company’s sales reached USD 232 million, marking a 7% increase from the previous year, with a notable 9% organic growth in the Prosthetics & Neuro Orthotics segment. The EBITDA margin stood strong at 21%, driven by efficient manufacturing and cost discipline. However, the Bracing & Supports segment saw a slight decline, and Patient Care sales remained flat. Embla Medical is narrowing its full-year guidance for organic sales growth to 5-6%, while maintaining the EBITDA margin guidance at 20-21%. Looking ahead, the company anticipates continued growth in its core Prosthetics segment, supported by new product launches and strategic investments, such as the acquisition of a majority share in Streifeneder ortho.production GmbH.